Özet:

Purpose: Common stage-small cell lung cancer (ES-SCLC) is known, and in the first stage we have studied the factors affecting the full response to treatment (CR) and the survival effect of the level of response to treatment in patients receiving cysplatin and etoposide combination chemotherapy. Method: In this retrospective study, 140 patients diagnosed with ES-SCLC were examined. According to the first stage post-chemotherapy radiological response assessment, two groups were identified as CR and non-CR (non-CR). Clinical, demographic characteristics of the patient and pre-treatment hemogram parameters were obtained from the archive. Results: 34 patients (24.3%) were CR, 106 (75.7%) were non-CR patients. In the single variable analysis, the diagnosis was found as predictive factors for the immediate absence of brain metastasis, taking 6 chemotherapy cycles and good performance CR (respectively p<0,001; p=0,020; p=0,001). In the multi-variable analysis, the absence of metastases in the brain and good performance were determined as independent predictive factors for CR (respectively p=0,033; p=0,019). The first stage chemotherapy response increased and the non-sick survival period and the general survival period increased (regularly log-rank p<0,001; log-rank p<0,001). The diagnosis is the immediate absence of brain metastases and good performance are independent predictive factors for the full response to the first stage of treatment. Patients with a complete response have a significantly longer rescue than the lower response to treatment.

Anahtar Kelimeler: